Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Ratio Therapeutics closes $70 million Series C financing to advance clinical development and expand manufacturing infrastructure.

PRIVATEJul 31, 2026•9 days ago

Amount Raised

$70 Million

Round Type

Series C

BostonBiotechnologyTherapeuticsPharmaceutical

Investors

Wasatch GroupEli Lilly And CompanyCatalio Capital ManagementBristol Myers SquibbDuquesne Family Office

Description

Ratio Therapeutics, Inc. announced the closing of a $70 million Series C financing. The financing included participation from both existing and new investors. Proceeds will be used to advance the ATLAS study and expand the company's pipeline and manufacturing capabilities

Company Information

Company

Ratio Therapeutics

Location

Boston, Massachusetts, United States

About

Ratio Therapeutics Inc. is a Boston-based pharmaceutical company with the mission to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms. Founded by John Babich, Ph.D., and Jack Hoppin, Ph.D., the company currently employs a growing team of radiopharmaceuticals discovery and development experts with backgrounds in the life science industry. Ratio's fully integrated proprietary R&D platforms, TrilliumTM and MacropaTM, enable the imaging, discovery and advancement of novel radiopharmaceuticals that have first/best-in-class delivery, safety and efficacy properties. The tunable nature of the company's platforms enables the efficient and timely generation of numerous novel radiopharmaceuticals for a broad range of high unmet need in solid tumors. Built to be the radiopharmaceuticals discovery and development partner of choice, Ratio currently collaborates with Bayer and Lantheus. Please visit www.ratiotx.com for more information and follow us on Twitter and LinkedIn.

Predictive Intelligence
Strategic

ML-powered predictions for Ratio Therapeutics's next move

Learn about Strategic plan

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.